Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Fig. 4

Improvements in physical function among PsA patients receiving apremilast 30 mg up to 260 weeks. Data as observed. The analysis includes all patient data, including the placebo-controlled phase, regardless of when the patients started taking apremilast (baseline, week 16, or week 24). The proportions of patients achieving a Health Assessment Questionnaire-Disability Index (HAQ-DI) minimal clinically important difference (MCID) of ≥ 0.35 at study visits up to week 260 are shown. n represents the number of patients with data available at that time point

Back to article page